AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Phio Pharmaceuticals shares fall 4.74% premarket after entering a drug substance development agreement.
ByAinvest
Tuesday, Jul 29, 2025 4:44 am ET1min read
Phio Pharmaceuticals Corp. fell 4.74% in premarket trading, with the company announcing a comprehensive drug substance development services agreement with a U.S. manufacturer. This agreement includes analytical and process development and cGMP manufacture of Phio's lead clinical development compound PH-762, marking a critical step in advancing its intratumoral program to treat cutaneous carcinomas. The company is currently enrolling patients for the 5th and expected final cohort in its Phase 1b dose escalation study for cutaneous squamous cell carcinoma, Merkel cell.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet